Albert Labs International Corp. has announced the filing of a New International PCT Patent Application (No. PCT/CA2022/051281) with the United States Patent and Trademark Office (USPTO) for its proprietary manufacturing process.

This proprietary manufacturing methodology developed and validated in-house at Albert Labs' Vancouver facility facilitates the production and scaling of highly potent yields of its KRN-101 Active Pharmaceutical Ingredient. The bioreactor technology is efficient, economical, and sustainable, ensuring pharmaceutical quality and consistent production of its natural, tryptamine-based medicines The Company is utilising this proprietary manufacturing technology to produce its primary drug target, the psilocybin-based KRN-101, which will treat cancer patients suffering from mental distress. It will also support the company's growth plans as it pursues a clinical expansion strategy with various global regulatory authorities.

Albert Labs is a pharmaceutical drug development company, focussed on gaining regulatory approval for active compounds in the treatment of mental health, and providing rapid access to effective prescription medicines for people suffering from mental health disorders. Its team of experts leverage advanced culture technology and natural extraction, coupled with a comprehensive regulatory approach, to accelerate the development of mental health drugs, for which the needs are both urgent and unmet. Albert Labs looks to develop solutions through an approved, fast track clinical pathway focusing on Real World Evidence (RWE).

RWE studies are an increasingly recognised clinical route, heavily used in oncology and recently, in the successful development of COVID-19 vaccines. Through collaborations with research institutions, hospital centres and government agencies, Albert Labs uses existing clinical infrastructure to deliver and improve patient access to its treatment. Albert Labs' first drug target, KRN-101, is a potential solution for cancer-related anxiety, a market of over 15 million people with roughly 1 million new sufferers each year.

From this initial focus, Albert Labs will address broader mental health concerns, reported to affect over a billion people worldwide. The company's goal is to deliver effective medicines to suffers with mental health concerns in the shortest possible time without compromising safety and/or quality, while also providing significant returns to shareholders.